Does bilirubin act as a free radical quencher of clinical significance in neonates and children?

Journal of Pediatric Biochemistry

Volumn 1, Issue 1, 2010, Pages 29-37

  Breimer, Lars H ^a  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bilirubin; hyperbilirubinemia guidelines; neonates; reactive oxygen species

Indexed keywords

BILIRUBIN; BILIVERDIN; CARBON MONOXIDE; GLUCURONOSYLTRANSFERASE 1A1; HEME OXYGENASE; HEMOGLOBIN; REACTIVE OXYGEN METABOLITE; URIC ACID;

AEROBIC METABOLISM; ANTIOXIDANT ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHILD; GILBERT DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERBILIRUBINEMIA; ISCHEMIC HEART DISEASE; JAUNDICE; NEUROTOXICITY; NEWBORN; OXIDATIVE STRESS; PRIORITY JOURNAL; RETROLENTAL FIBROPLASIA; UDP GLUCURONYLTRANSFERASE 1A1 GENE; URIC ACID BLOOD LEVEL;

ANIMALIA;

EID: 79959243403     PISSN: 18795390     EISSN: 18795404     Source Type: Journal    
DOI: 10.3233/JPB-2010-0001     Document Type: Article

References (79)

1. R. Kliegman, R.E. Behrman, H.B. Jenson et al., Nelson Textbook of Pediatrics: 18th Edition, WB Saunders Co, 2009. Philadelphia, PA, USA. PA.
2. Dennery, D.S. Seidman and D.K. Stevenson, Neonatal hyperbilirubinemia, N Engl J Med 344 (2001), 581-590.
3. S.M. Shapiro, Definition ofthe clinical spectrum of kernicterus and bilirubin-induced neurologic dysfunction (BIND), J Perinatol 25 (2005), 54-59. (Pubitemid 40207656)
4. R. Brodersen, Bilirubin transport in the newborn infant, re-viewed with relation to kernicterus, JPediatr 96 (1980), 349-356. (Pubitemid 10147517)
5. M.J. Maisels and T.B. Newman, Surveillance of severe neona-tal hyperbilirubinemia: a view from south of the border, CMAJ 175 (2006), 599-600. (Pubitemid 44439720)
6. R.P. Wennberg, C.E. Ahlfors, V.K. Bhutani, L.H. Johnson and S.M. Shapiro, Towardunderstanding kernicterus: achallenge to improve the management ofjaundiced newborns, Pediatrics 117 (2006), 474-485. (Pubitemid 46071611)
7. American Academy of Pediatrics Subcommittee on Hyper-bilirubinemia. Management of hyperbilirubinemia inthe new-born infant 35 or more weeks of gestation, Pediatrics 114 (2004), 297-316.
8. A.L. Alkalay and C.F. Simmons, Hyperbilirubinemia Guide-lines in Newborn Infants, Pediatrics 115 (2005), 824-825.
9. M.J. Maisels, V.K. Bhutani, D. Bogen, T.B. Newman, A.R. Starkand J.F. Watchko, Hyperbilirubinemia inthenewborn in-fant
10. V.K. Bhutani, G.R. Gourley, S. Adler, B. Kreamer, C. Dalin and L.H. Johnson, Noninvasive measurement of total serum bilirubin in a multiracial predischarge newborn population to assess the risk of severe hyperbilirubinemia, Pediatrics 106 (2000), E17.
11. M.J. Maisels, E.M. Ostrea, S. Touch et al., Evaluation of a new transcutaneous bilirubinometer, Pediatrics 113 (2004), 1628-1635. (Pubitemid 38697968)
12. W.D. Engle, G.L. Jackson, dD. Sendelbach, D. Manning and W.H. Frawley, Assessment of a transcutaneous device in the evaluation of neonatal hyperbilirubinemia in a primarily His-panic population, Pediatrics 110 (2002), 61-67. (Pubitemid 34742641)
13. K. Grohmann, M. Roser, B. Rolinski, I. Kadow, C. Müller, A. Goerlach-Graw, M. Nauck and H. Küster, Bilirubin measure-ment for neonates: comparison of 9 frequently used methods, Pediatrics 117 (2006), 1174-1183. (Pubitemid 46071510)
14. T. Karen, H.U. Bucher and J.C. Fauchère, Comparison of a new transcutaneous bilirubinometer (Bilimed) with serum bilirubin measurements in preterm and full-term infants, BMC Pediatrics 9 (2009), 70.
15. M.J. Maisels, Historical perspectives: transcutaneous biliru-binometry, NeoReviews 7 (2006), 217-225.
16. M.S. Skae, J. Moise and P. Clarke, Is current management of neonatal jaundice evidence based? Arch Dis Child Fetal Neonatal Ed 90 (2005), F540.
17. W.S. Park, Y.S. Chang, S.H. Chung, D.W. Seo, S.H. Hong and M.Lee, Effect of hypothermia on bilirubin-induced alterations in brain cell membrane function and energy metabolism in newborn piglets, BrainRes 922 (2001), 276-281. (Pubitemid 34017490)
18. A.F. McDonagh and J.M. Maisels, Bilirubin unbound: dejà vu all over again? Pediatrics 117 (2006), 523-525. (Pubitemid 46071616)
19. S.W. Ryter, J. Alam and A.M. Choi, Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications, Physiol Rev 86 (2006), 583-650.
20. R. Carmel, E.T. Wong, J.M. Weiner and C.S. Johnson, Racial differences in serum total bilirubin levels in health and in disease (pernicious anemia), JAMA 253 (1985), 3416-3418. (Pubitemid 15056649)
21. L.H. Breimer and D.P. Mikhailidis, Could carbon monoxide and bilirubin be friends as well as foes of the body? ScandJ Clin Lab Invest 70 (2010), 1-5.
22. M. Madhavan, W.A. Wattigney, S.R. Srinivasan and G.S. Berenson, Serum bilirubin distribution and its relation to car-diovascular risk in children and young adults, Atherosclerosis 131 (1997), 107-113. (Pubitemid 27240103)
23. D.E. Barnes and T. Lindahl, Repair and genetic consequences of endogenous DNA base damage in mammalian cells, Annu Rev Genet 38 (2004), 445-476. (Pubitemid 40013735)
24. L.H. Breimer, Molecular mechanisms of oxygen radical car-cinogenesis and mutagenesis: the role of DNA base damage, MolCarcinog3(1990), 188-197. (Pubitemid 20335528)
25. L.H. Breimer, Repair of DNA damage induced by reactive oxygen species, FreeRadicRes Commun 14 (1991), 159-171.
26. R.D. Wood, M. Mitchell, J. Sgouros and T. Lindahl, Human DNA Repair Genes, Science 291 (2001), 1284-1289. (Pubitemid 32173086)
27. D. Steinberg, S. Parthasarathy, T.E. Carew, J.C. Khoo and J.L. Witztum, Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity, N Engl J Med 320 (1989), 915-924. (Pubitemid 19101597)
28. D. Alabanes, Vitamin supplements and cancer prevention: where do randomized controlled trials stand? J Natl Cancer Inst 101 (2009), 2-4.
29. G. Bjelakovic, D. Nikolova, L.L. Gluud, R.G. Simonetti and C. Gluud, Mortality in randomized trials of antioxidant sup-plements for primary and secondary prevention: systematic review and meta-analysis, JAMA 297 (2007), 842-857. (Pubitemid 46333949)
30. L.H. Kuller, A time to stop prescribing antioxidant vitamins to prevent and treat heart disease? Arterioscler Thromb Vasc Biol21 (2001), 1253.
31. B.N. Ames, R. Cathcart, E. Schwiers and P. Hochstein, Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis, Proc Natl Acad Sci USA 78 (1981), 6858-6862. (Pubitemid 12216861)
32. R. Stocker, Y. Yamamoto, A.F. McDonagh, A.N. Glazer and B.N. Ames, Bilirubin is an antioxidant ofpossible physiolog-ical importance, Science 235 (1987), 1043-1046. (Pubitemid 17049750)
33. R. Stocker, A.N. Glazer and B.N. Ames, Antioxidant activ-ity of albumin-bound bilirubin, Proc Natl Acad Sci USA 84 (1987), 5918-5922.
34. R. Stocker and B.N. Ames, Potential role ofconjugated biliru-bin and copper in the metabolism of lipid peroxides in bile, Proc Natl Acad Sci USA 84 (1987), 8130-8134.
35. J.M. McCord and I. Fridovich, Superoxide dismutase. An en-zymic function for erythrocuprein (hemocuprein), JBiol Chem 244 (1969), 6049-6055.
36. S.L. Marklund, Human copper-containing superoxide dismutase of high molecular weight, Proc Natl Acad Sci USA 79 (1982), 7634-7638. (Pubitemid 13173159)
37. N.J. Miller, C. Rice-Evans, M.J. Davies, V. Gopinathan and A. Milner, A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates, Clin Sci (Lond) 84 (1993), 407-412. (Pubitemid 23113948)
38. V. Gopinathan, N.J. Miller, A.D. Milner and C.A. Rice-Evans, Bilirubin and ascorbate antioxidant activity in neonatal plas-ma,FEBSLett349(1994), 197-200. (Pubitemid 24263261)
39. C. Hammerman, R. Goldstein, M. Kaplan et al., Bilirubin in the premature: toxic waste ornatural defense? Clin Chem 44 (1998), 2551-2553. (Pubitemid 28565674)
40. C. Dani, E. Martelli, G. Bertini et al., Plasma bilirubin level and oxidative stress in preterm infants, Arch Dis Child Fetal Neonatal Ed 88 (2003), 119-123.
41. S.F. Asad, S. Singh, A. Ahmad and S.M. Hadi, Bilirubin/biliverdin-Cu(II) induced DNAbreakage; reaction mechanism andbiologicalsignificance, Toxicol Lett 131 (2002), 181-189. (Pubitemid 34454874)
42. P. Van Bergen, P. Rauhala, C.M. Spooner and C.C. Chiueh, Hemoglobin and iron-evoked oxidative stress in the brain: pro-tection by bile pigments, manganese and Snitrosoglutathione, FreeRadicRes 31 (1999), 631-640.
43. T.W. Sedlak and S.H. Snyder, Bilirubin benefits: cellular pro-tection by a biliverdin reductase antioxidant cycle, Pediatrics 113 (2004), 1776-1782. (Pubitemid 38697991)
44. T.W. Sedlak, M. Saleh, D.S. Higginson, B.D. Paul, K.R. Juluri and S.H. Snyder, Bilirubin and glutathione have complemen-tary antioxidant and cytoprotective roles, Proc Natl Acad Sci USA 106 (2009), 5171-5176.
45. G.J. Maghzal, M.C. Leck, E. Collinson, C. Li and R. Stock-er, Limited role for the bilirubin-biliverdin redox amplifica-tion cycle in the cellular antioxidant protection by biliverdin reductase, JBiol Chem 284 (2009), 29251-29259.
46. D.A. Benaron and F.W. Bowen, Variation of initial serum bilirubin rise in newborn infants with type of illness, Lancet 338 (1991), 78-81.
47. D.D. Gaton, J. Gold, R. Axer-Siegel, E. Wielunsky, N. Naor and I. Nissenkorn, Evaluation of bilirubin aspossible protec-tive factor in the prevention of retinopathy of prematurity, Br JOphthalmol 75 (1991), 532-534.
48. J.C. Fauchère, F.E. Meier-Gibbons, F. Koerner and E. Bossi, Retinopathy ofprematurity and bilirubin-no clinical evidence for a beneficial role of bilirubin as a physiological anti-oxidant, EurJPediatr 153 (1994), 358-362. (Pubitemid 24137455)
49. M.G. Romeo, L.G. Tina, A. Scuderi, M. Di Pietro, M. Carac-ciolo and G. Distefano, Variations of blood bilirubin levels in the newborn with and without retinopathy of prematurity (ROP), PediatrMed Chir 16 (1994), 59-62, (in Italian).
50. M.H. DeJonge, A. Khuntia, M.J. Maisels and A. Bandagi, Bilirubin levels and severe retinopathy of prematurity in in-fants with estimated gestational ages of 23 to 26 weeks, J Pediatr 135 (1999), 102-104. (Pubitemid 30180571)
51. J.D. Milner, H.Z. Aly, L.B. Ward and A. El-Mohandes, Does elevated peak bilirubin protect from retinopathy ofprematurity in very low birthweight infants, J Perinatol 23 (2003), 208-211. (Pubitemid 36656521)
52. L. Novotny and L. Vitek, Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of pub-lished studies, Exp Biol Med (Maywood) 228 (2003), 568-571. (Pubitemid 37203679)
53. M. Fulks, R.L. Stout and V.F. Dolan, Mortality associated with bilirubin levels in insurance applicants, J Insur Med 41 (2009), 49-53.
54. E.H. Temme, J. Zhang, E.G. Schouten and H. Kesteloot, Serum bilirubin and 10-year mortality risk in a Belgian popu-lation, Cancer Causes Control 12 (2001), 887-894. (Pubitemid 34048869)
55. A.M. Strasak, K. Rapp, W. Hilbe et al., The role of serum uric acid as an antioxidant protecting against cancer: prospective study in more than 28 000 older Austrian women, Ann Oncol 18(2007), 1893-1897.
56. A.R. Bhuiyan, S.R. Srinivasan, W. Chen, A. Sultana and G.S. Berenson, Association of serum bilirubin with pulsatile arterial function in asymptomatic young adults: the Bogalusa Heart Study, Metabolism 57 (2008), 612-616. (Pubitemid 351608221)
57. B. Foresti, M.G. Bani-Hani and R. Motterlini, Use of carbon monoxide as a therapeutic agent: promises and challenges, Intensive Care Med34 (2008), 649-658.
58. L.E. Otterbein, Carbon monoxide: innovative anti-inflamm-atory properties of an age-old gas molecule, Antioxid Redox Signal 4 (2002), 309-319. (Pubitemid 34517182)
59. R. Ollinger, H. Wang, K. Yamashita et al., Therapeutic applications of bilirubin and biliverdin intransplantation, Antioxid Redox Signal 9 (2007), 2175-2185. (Pubitemid 350059026)
60. C. Ceran, K. Sonmez, Z. Turkyllmaz et al., Effect of bilirubin in ischemia/reperfusion injury on rat small intestine, JPediatr Surg36 (2001), 1764-1767. (Pubitemid 33131679)
61. B. Demirogullari, G. Ekingen, G. Guz et al., A comparative study of the effects of hemin and bilirubin on bilateral renal ischemia reperfusion injury, Nephron Exp Nephrol 103 (2006), 1-5.
62. H. Wang, S.S. Lee, C. Dell'Agnello etal., Bilirubincaninduce tolerance to islet allografts, Endocrinology 147 (2006), 762-768.
63. K. Sato, J. Balla, L. Otterbein et al., Carbon monoxide gener-ated by heme oxygenase-1 suppresses the rejection ofmouse-to-rat cardiac transplants, J Immunol 166 (2001), 4185-4194. (Pubitemid 32224952)
64. J.M. Hoskins and H.L. McLeod, UGT1A and irinotecan toxi-city: keeping it in the family, J Clin Oncol 27 (2009), 2457-2465.
65. R. Olsson, A. Bliding, R. Jagenburg et al., Gilbert's syn-drome-does it exist? A study of the prevalence ofsymptoms inGilbert's syndrome,Acta Med Scand224(1988), 485-490. (Pubitemid 19052198)
66. Y. Maruo and H. Sato, UDP-Glucuronosyltransferase, Nippon Eiseigaku Zasshi 56 (2002), 629-633 (in Japanese).
67. S. Yusoff, H. Van Rostenberghe, N.M. Yusoff et al., Frequencies of A(TA)7TAA, G71R, and G493Rmutations ofthe UGT1A1 gene in the Malaysian population, Biol Neonate 89 (2006), 171-176.
68. L.H. Breimer, K.A. Spyropolous, A.F. Winder, D.P. Mikhailidis and G. Hamilton, Is bilirubin protective against coronary artery disease? Clin Chem 40 (1994), 1987-1988. (Pubitemid 24332717)
69. L. Vitek, M. Jirsa, M. Brodanova et al., Gilbert syndrome and ischemic heart disease: aprotective effect ofelevated bilirubin levels, Atherosclerosis 160 (2002), 449-456. (Pubitemid 34159340)
70. V Gajdos, F.M. Petit, C. Perret et al., Further evidence that the UGT1A1*28 allele is not associated with coronary heart disease: the ECTIM Study, Clin Chem 52 (2006), 2313-2314. (Pubitemid 44925016)
71. A. Lingenhel, B. Kollerits, J.P. Schwaiger et al., Serum biliru-bin levels, UGT1A1 polymorphisms and risk for coronary artery disease, Exp Gerontol 43 (2008), 1102-1107.
72. B. Rantner, B. Kollertis, M. Anderwald-Stadler et al., Asso-ciation between the UGT1A1 TA-repeat polymorphism and bilirubin concentration in patients with intermittent claudica-tion: results from the CAVASIC study, Clin Chem 54 (2008), 851-857. (Pubitemid 351671602)
73. J.P. Lin, C.J. O'Donnell, J.P. Schwaiger et al., Association betweentheUGT1A1*28allele, bilirubinlevels, andcoronary heart disease inthe Framingham Heart Study, Circulation 114 (2006), 1476-1481. (Pubitemid 44527002)
74. P.J. Bosma, J.R. Chowdhury, C. Bakker et al., The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome, N Engl J Med333(1995), 1171-1175.
75. Z. Ahmad, M. Salim and M.D. Maines, Human biliverdin reductase is a leucine zipper-like DNA-binding protein and functions intranscriptional activation of heme oxygenase-1 by oxidative stress, JBiol Chem 277 (2002), 9226-9232. (Pubitemid 34953003)
76. U.M. Florczyk, A. Jozkowicz and J. Dulak, Biliverdin reduc-tase: new features of an old enzyme and its potential thera-peutic significance, Pharmacol Rep 60 (2008), 38-48. (Pubitemid 351586541)
77. B. Wegiel, C.J. Baty, D. Gallo et al., Cell surface biliverdin re-ductase mediates biliverdin-induced anti-inflammatory effects via phosphatidylinositol 3-kinase and Akt, J Biol Chem 284 (2009), 21369-21378.
78. A. Sandouka, B.J. Fuller, B.E. Mann, C.J. Green, R. Foresti and R. Motterlini, Treatment with CO-RMs during cold stor-age improves renal function at reperfusion, Kidney Int 69 (2006), 239-247. (Pubitemid 43323073)
79. J. Varadi, I. Lekli, B. Juhasz et al., Beneficial effects of carbon monoxide-releasing molecules on post-ischemic myocardial recovery, Life Sci 80 (2007), 1619-1626. (Pubitemid 46412364)